Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 69 of 5804
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this s…
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for tough breast cancers: major trial launches
Disease control OngoingThis is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New pill combo aims to outsmart leukemia in major trial
Disease control OngoingThe main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QB…
Phase: PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
MRI vs ultrasound: which scan saves more lives from liver cancer?
Prevention Recruiting nowThe study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care scr…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New hope for babies with leukemia: immunotherapy combo trial launches
Disease control Recruiting nowThe purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Phase: PHASE1, PHASE2 • Sponsor: Tanja Andrea Gruber • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Targeted pill shows promise for Hard-to-Treat lung cancer subtype
Disease control OngoingThis is a phase III, open-label, single-arm, multicenter study designed to evaluate the anti-tumor activity and safety of SY-5007 administered orally to participants with locally advanced or metastatic RET-positive NSCLC.
Phase: PHASE3 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced breast cancer: SKB264 trial launches
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo targets gene mutation
Disease control Recruiting nowThe goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palb…
Phase: PHASE3 • Sponsor: LeonaBio • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail aims to fight deadly eye cancer
Disease control OngoingThis is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ip…
Phase: PHASE2, PHASE3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New immunotherapy combo aims to outperform standard lung cancer treatment
Disease control Recruiting nowThis is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progressio…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New antibody drug aims to tame ulcerative colitis in major trial
Disease control OngoingThe purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achiev…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail targets deadly bowel cancer mutation
Disease control Recruiting nowThis is a multicenter, randomized, open-label, Phase 3 study
Phase: PHASE3 • Sponsor: Shanghai Kechow Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:30 UTC
-
New hope for lung cancer: experimental drug volrustomig takes on standard therapy
Disease control OngoingThe purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Gene therapy injection aims to repair failing hearts
Disease control OngoingThis is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age \>18 years with non-ischemic ca…
Phase: PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New triple therapy aims to stop pancreatic Cancer's return after surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal ade…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Weight-Loss drug tirzepatide put to the test in teens
Disease control OngoingThe main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have com…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for advanced breast cancer: targeted drug combo under trial
Disease control OngoingTo evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New CAR T-Cell combo aims to stop myeloma in its tracks
Disease control OngoingThe purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologou…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to cure hepatitis b in over half of patients
Disease control Recruiting nowHepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of HBV treatment. However, HBsAg loss can be achieved…
Phase: PHASE2 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Disease control
Last updated Jun 26, 2026 15:29 UTC